Mind Medicine (MindMed) Inc. Stock Price

NasdaqGS:DFTX Community·US$1.5b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
68 Fair Values set on narratives written by author

Create a narrative

DFTX Share Price Performance

US$15.38

8.87 (136.25%)

US$15.38

8.87 (136.25%)

US$15.38

Fri, 16 Jan 26

Share Pricen/a

DFTX Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks

1 Reward

View Full Analysis

Mind Medicine (MindMed) Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -1.71
: 0%
: 0%
: 30.9%

View Full Analysis

About DFTX

Founded: n/a
Employees: 74
CEO: Robert Barrow
WebsiteView website: www.mindmed.co

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.